Sera Prognostics, Inc. (SERA)Healthcare | Medical Devices | Salt Lake City, United States | NasdaqGM
1.92 USD
-0.05
(-2.538%) ⇩
(July 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 6:07 a.m. EDT
The investment case for Sera Prognostics is fundamentally broken, rendering any short-term technical bounce irrelevant. The company is hemorrhaging cash with operating losses exceeding $26 million and free cash flow of nearly -$19 million, while revenue has collapsed by 63% year-over-year. The balance sheet is precarious, with debt-to-equity at 3.7 and negative returns on both assets and equity. While the stock recently rallied off its lows, this appears to be a dead-cat bounce fueled by penny-stock hype rather than operational recovery; the underlying business is deteriorating rapidly. The options market confirms this pessimism, with almost no call buying and defensive put positioning at key strikes. There is no catalyst here to justify a long position, and the risk of permanent capital loss remains extreme. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.072200 |
| AutoARIMA | 0.079234 |
| AutoETS | 0.079236 |
| MSTL | 0.081452 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 38% |
| H-stat | 0.19 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.681 |
| Excess Kurtosis | -0.60 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 3.705 |
| Revenue per Share | 0.001 |
| Market Cap | 75,184,752 |
| Forward P/E | -3.33 |
| Beta | 0.97 |
| Website | https://www.sera.com |
As of July 11, 2026, 6:07 a.m. EDT: Options activity is sparse and lacks directional conviction. Call volume is negligible across all expirations, while put open interest is concentrated in the January 2027 expiration at the $2.50 strike, suggesting a speculative hedge against further downside rather than a bullish setup. Implied volatility remains extremely low, indicating a lack of active speculation on either side.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.28888887 |
| Address1 | 2,749 East Parleys Way |
| Address2 | Suite 200 |
| All Time High | 15.5 |
| All Time Low | 1.1 |
| Ask | 2.5 |
| Ask Size | 2 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 27,880 |
| Average Daily Volume3 Month | 49,829 |
| Average Volume | 49,829 |
| Average Volume10Days | 27,880 |
| Beta | 0.97 |
| Bid | 1.45 |
| Bid Size | 2 |
| Book Value | 1.727 |
| City | Salt Lake City |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.92 |
| Current Ratio | 2.123 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 2.03 |
| Day Low | 1.92 |
| Debt To Equity | 3.705 |
| Display Name | Sera Prognostics |
| Earnings Call Timestamp End | 1,778,101,200 |
| Earnings Call Timestamp Start | 1,778,101,200 |
| Earnings Timestamp | 1,778,097,600 |
| Earnings Timestamp End | 1,785,960,000 |
| Earnings Timestamp Start | 1,785,960,000 |
| Ebitda | -35,813,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.846 |
| Enterprise To Revenue | 531.382 |
| Enterprise Value | 30,288,752 |
| Eps Current Year | -0.68 |
| Eps Forward | -0.57667 |
| Eps Trailing Twelve Months | -0.64 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 801 990 6601 |
| Fifty Day Average | 1.9311 |
| Fifty Day Average Change | -0.011100054 |
| Fifty Day Average Change Percent | -0.005748047 |
| Fifty Two Week Change Percent | -28.888887 |
| Fifty Two Week High | 3.95 |
| Fifty Two Week High Change | -2.0300002 |
| Fifty Two Week High Change Percent | -0.5139241 |
| Fifty Two Week Low | 1.56 |
| Fifty Two Week Low Change | 0.36 |
| Fifty Two Week Low Change Percent | 0.23076925 |
| Fifty Two Week Range | 1.56 - 3.95 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,626,355,800,000 |
| Float Shares | 27,462,797 |
| Forward Eps | -0.57667 |
| Forward P E | -3.3294604 |
| Free Cashflow | -18,903,124 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 71 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | -1.91228 |
| Gross Profits | -109,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.115030006 |
| Held Percent Institutions | 0.51035 |
| Implied Shares Outstanding | 39,158,725 |
| Industry | Medical Devices |
| Industry Disp | Medical Devices |
| Industry Key | medical-devices |
| Ipo Expected Date | 2,021-07-15 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation. It is also involved in the development of a pipeline of novel blood-based biomarker tests and predictive analytic products and services for pregnancy related conditions, such as time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah. |
| Long Name | Sera Prognostics, Inc. |
| Market | us_market |
| Market Cap | 75,184,752 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_117852744 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -32,140,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 76,751,100 |
| Number Of Analyst Opinions | 2 |
| Open | 1.97 |
| Operating Cashflow | -26,844,000 |
| Operating Margins | -668.5714 |
| Payout Ratio | 0.0 |
| Phone | 801 990 0520 |
| Previous Close | 1.97 |
| Price Eps Current Year | -2.8235292 |
| Price Hint | 4 |
| Price To Book | 1.1117544 |
| Price To Sales Trailing12 Months | 1,319.0308 |
| Profit Margins | 0.0 |
| Quick Ratio | 2.025 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | -0.0500001 |
| Regular Market Change Percent | -2.53807 |
| Regular Market Day High | 2.03 |
| Regular Market Day Low | 1.92 |
| Regular Market Day Range | 1.92 - 2.03 |
| Regular Market Open | 1.97 |
| Regular Market Previous Close | 1.97 |
| Regular Market Price | 1.92 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 30,925 |
| Return On Assets | -0.21616 |
| Return On Equity | -0.39581 |
| Revenue Growth | -0.632 |
| Revenue Per Share | 0.001 |
| Sand P52 Week Change | 0.20365608 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 38,190,966 |
| Shares Percent Shares Out | 0.0067000003 |
| Shares Short | 262,549 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 297,212 |
| Short Name | Sera Prognostics, Inc. |
| Short Percent Of Float | 0.0085 |
| Short Ratio | 5.67 |
| Source Interval | 15 |
| State | UT |
| Symbol | SERA |
| Target High Price | 6.0 |
| Target Low Price | 5.0 |
| Target Mean Price | 5.5 |
| Target Median Price | 5.5 |
| Total Cash | 47,401,000 |
| Total Cash Per Share | 1.21 |
| Total Debt | 2,505,000 |
| Total Revenue | 57,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.64 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.589875 |
| Two Hundred Day Average Change | -0.669875 |
| Two Hundred Day Average Change Percent | -0.2586515 |
| Type Disp | Equity |
| Volume | 30,925 |
| Website | https://www.sera.com |
| Zip | 84,109 |